HANCLARO

This brand name is authorized in Nigeria.

Active ingredients

The drug HANCLARO contains one active pharmaceutical ingredient (API):

1	Clarithromycin UNII H1250JIK0A - CLARITHROMYCIN
	Clarithromycin is a semi-synthetic derivative of erythromycin A. It exerts its antibacterial action by selectively binding to the 50s ribosomal sub-unit of susceptible bacteria preventing translocation of activated amino acids. It inhibits the intracellular protein synthesis of susceptible bacteria.
	Read more about Clarithromycin

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
B4-3751	Tablet	Hanclaro 500 Tablets TAB 500 mg	HANCLARO 500 TABLETS B4-3751 HANCLARO 500 TABLETS CLARITHROMYCIN 500MG, Q.S Tablet Prescription Only Medicine (POM) HANBET PHARMACEUTICALS LIMITED, , MURTALA MOHAMMED WAY, EBUTE-METTA LAGOS Nigeria JIANGSU RUINIAN QIANJIN PHARMACEUTICAL. CO., LTD., CHUANBU VILLAGE, DINGSHU TOWN, YIXING CITY, JIANGSU PROVINCE CHINA, China 26/01/2023 25/01/2028	26/01/2023

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J01FA09	Clarithromycin	J Antiinfectives for systemic use → J01 Antibacterials for systemic use → J01F Macrolides, lincosamides and streptogramins → J01FA Macrolides
Discover more medicines within J01FA09

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	B4-3751